Association between social determinants of health and time to treatment for newly diagnosed multiple myeloma.
Hamlet Gasoyan,Faiz Anwer,Jeffrey D. Kovach,Nicholas J. Casacchia,Ming Wang,Michael B. Rothberg
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.1583
IF: 45.3
2024-05-31
Journal of Clinical Oncology
Abstract:1583 Background: Delayed access to costly anti-myeloma agents due to insurance precertification process or out-of-pocket costs results in treatment initiation with less-costly corticosteroids in some patients with newly diagnosed multiple myeloma (NDMM). Less is known about the scope of the delay and the factors associated with it. Methods: This retrospective cohort study used Taussig Cancer Center’s Myeloma Patient Registry to identify adults with NDMM between January 1, 2017 and December 31, 2021. Electronic health records data captured (1) time from initial diagnosis to receipt of FDA-approved anti-myeloma agent including vs. excluding corticosteroids, (2) time to initial prescription fill for FDA-approved anti-myeloma drug excluding corticosteroids, and (3) association of race, sex, primary insurance type, area deprivation index (ADI), urbanicity, and time to initial fill for anti-myeloma drug excluding corticosteroids. The latter was examined via cumulative incidence at 30 days since initial diagnosis using the log-rank test and multivariable Cox regression model. Results: We identified 723 patients with a mean age at diagnosis of 67 years ±11; 55% were male, 77% White, 22% Black, and 1% other races, covered by private insurance (36%), traditional Medicare (28%), Medicare Advantage (25%), Medicaid (8.4%), and self-pay/other (1.8%); and median follow-up of 784 days (interquartile range [IQR], 415, 1313). Over a third of patients (37%) resided in an area in the most disadvantaged quartile of the ADI; 83% resided in a metropolitan area. Median time to receipt of anti-myeloma treatment was 10 days (IQR, 2, 24) including corticosteroids vs. 18 days (IQR, 8, 37) excluding corticosteroids. Median time to initial prescription fill for an anti-myeloma drug excluding corticosteroids was 31 days (IQR, 16, 75). The cumulative incidence of prescription fill for anti-myeloma drug excluding corticosteroids at 30 days was 40% (95% CI, 36%, 44%) in White individuals, 28% (95% CI, 21%, 36%) in Black patients, and 17% (95% CI, 0.42%, 64%) in other races (P=.009) [adjusted HR for Black patients (v. White), 0.63, 95% CI, 0.44, 0.90]; 31% (95% CI, 25%, 38%) in patients with traditional Medicare, 37% (95% CI, 30%, 44%) with Medicare Advantage, 44% (95% CI, 38%, 50%) with Private Insurance, 34% (95% CI, 23%, 48%) with Medicaid, and 31% (95% CI, 9.1%, 61%) self-paying/with other insurance (P=.07) [adjusted HR for private insurance (v. traditional Medicare), 1.41, 95% CI, 1.04, 1.93]; 40% (95% CI, 36%, 44%) treated in Taussig Cancer Center and 25% (95% CI, 17%, 34%) in regional hospitals (P=.003) [adjusted HR for regional hospitals, 0.59, 95% CI, 0.40, 0.89]. Conclusions: Disparities in time to prescription fill for anti-myeloma drugs exist based on socio-demographic factors. Future research should examine the role of precertification criteria and out-of-pocket costs in delays with recommended care.
oncology